Compositions and methods for treatment of ocular diseases

Abstract

The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.

We claim: 
     
         1 . An ocular composition, comprising:
 a shear-thinning hydrogel comprising hyaluronic acid, wherein the hyaluronic acid is at a concentration of about 3 to about 10 mg/ml and is covalently crosslinked; and   an antibiotic at a concentration of about 1 to about 10 mg/ml.   
     
     
         2 . The ocular composition of  claim 1 , wherein the hyaluronic acid is at a concentration of about 3, 4, 5, 6, 7, 8, 9, or 10 mg/ml. 
     
     
         3 . The ocular composition of  claim 1 , wherein the antibiotic is as a concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg/ml. 
     
     
         4 . The ocular composition of  claim 1 , wherein the hyaluronic acid is modified or unmodified hyaluronic acid. 
     
     
         5 . The ocular composition of  claim 1 , wherein the antibiotic has a solubility in water of about 1 mg/ml or greater. 
     
     
         6 . The ocular composition of  claim 1 , wherein the antibiotic is a fluoroquinolone. 
     
     
         7 . The ocular composition of  claim 6 , wherein the antibiotic is moxifloxacin or a salt of moxifloxacin. 
     
     
         8 . The ocular composition of  claim 7 , wherein the antibiotic is moxifloxacin hydrochloride. 
     
     
         9 . The ocular composition of  claim 6 , wherein the antibiotic is a salt of besifloxacin. 
     
     
         10 . The ocular composition of  claim 9 , wherein the antibiotic is besifloxacin hydrochloride. 
     
     
         11 . The ocular composition of  claim 1 , wherein the antibiotic is an aminoglycoside. 
     
     
         12 . The ocular composition of  claim 10 , wherein the antibiotic is tobramycin. 
     
     
         13 . The ocular composition of  claim 4 , wherein the modified hyaluronic acid is thiolated hyaluronic acid. 
     
     
         14 . The composition of  claim 4 , wherein the modified hyaluronic acid is thiolated carboxymethyl hyaluronic acid. 
     
     
         15 . The composition of  claim 13 , wherein the hydrogel is disulfide crosslinked. 
     
     
         16 . The composition of  claim 14 , wherein the hydrogel is disulfide crosslinked. 
     
     
         17 . An ocular composition comprising:
 a shear-thinning hydrogel comprising thiolated hyaluronic acid, wherein the thiolated hyaluronic acid is at a concentration of about 3 to about 10 mg/ml and is disulfide crosslinked; and   an antibiotic at a concentration of about 1 to about 10 mg/ml.   
     
     
         18 . The ocular composition of  claim 17 , wherein the thiolated hyaluronic acid is at a concentration of 3, 4, 5, 6, 7, 8, 9, or 10 mg/ml. 
     
     
         19 . The ocular composition of  claim 17 , wherein the antibiotic is at a concentration of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg/ml. 
     
     
         20 . The composition of  claim 17 , wherein the thiolated hyaluronic acid has a thiol modification of about 0.05 to about 1.0 μmol thiol/mg. 
     
     
         21 . The composition of  claim 20 , wherein the thiol modification is about 0.05 to about 0.2 μmol thiol/mg, and wherein the thiolated hyaluronic acid is at a concentration of about 6.5 to about 8.5 mg/ml. 
     
     
         22 . The composition of  claim 17 , wherein the antibiotic is a fluoroquinolone. 
     
     
         23 . The composition of  claim 22 , wherein the antibiotic is a salt of moxifloxacin. 
     
     
         24 . The composition of  claim 23 , wherein the antibiotic is moxifloxacin hydrochloride.